Nevertheless, our findings of consistently decreased SRRM4 expression across tumor types (Fig 2A), coupled with the correlation of SRRM4 expression with inclusion of its target exons in tumors (S4A Fig), and their significant overlap with exons increasing after SRRM4 overexpression in different cancer cell lines, provide strong evidence that SRRM4 dysregulation contributes substantially to the observed splicing changes in cancer. This evidence concerns the gene SRRM4 and neoplasm.